RxDoctor Payments Data

Rafael Baez Bonilla, MD

Nephrology · Fort Lauderdale, FLNPI 1427243310

Payments from drug & device makers

$174,619in general payments, 2019–2025

Across 443 payments — averaging $394.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$163K
  • Sobi, Inc$3K
  • Otsuka America Pharmaceutical, Inc.$3K
  • AstraZeneca$800
  • Travere Therapeutics, Inc.$738
  • Mallinckrodt Hospital Products Inc.$699
  • plus $4K from 24 others

What the payments were for

  • Consulting fees$5,3203%
  • Speaking & faculty fees$139,85280%
  • Travel & lodging$17,28910%
  • Food & beverage$11,9327%
  • Education$2260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,619 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$267,589
Medicare patients
605
Services billed
2,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol41$47,026
KerendiaFinerenone12$10,110
LokelmaSodium Zirconium Cyclosilicate13$10,001
ProsolParenteral Amino Acid 20% No.131$6,326
Calcium Acetate11$1,278
Nifedipine ErNifedipine21$806
Febuxostat12$589
Bumetanide11$517
Torsemide21$376
Allopurinol41$295
Losartan Potassium21$187
Lisinopril45$171
Spironolactone11$119
Hydralazine Hcl20$118
Furosemide18$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$800$57,02754 claims
BayerKerendia$346$10,11012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.

Other nephrology in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →